摘要
目的:评价三苯氧胺治疗乳腺增生病的疗效和安全性。方法:通过对MEDLINE、EMBASE、BIOSIS 以及Cochrane图书馆对照试验资料库,中国生物医学文摘数据库的机检和手工检索文献的参考文献,选取采用三苯氧胺和中药治疗乳腺增生病的临床对照试验,进行系统评价。中药的剂型、服用方法、疗程不限。结果:5篇试验,包含3089名患者符合纳入标准,其中有3篇提到随机分组。合并结果表明,三苯氧胺治疗乳腺增生病有一定疗效,[无效的相对危险度(relative risk,RR)为1．88,95％,可信区间(confidence intervals,CI)为0．22-15．72]。试验报告有明显副作用,但能在停药后逐渐消失。结论:根据本系统评价,三苯氧胺治疗乳腺增生病有一定疗效,但有可逆的不良反应。然而,由于试验的方法学质量普遍较低,且可能存在发表偏倚,所以目前尚无足够的证据支持它的疗效和安全性,还需要进一步规范的大样本试验。
Objective： To evaluate the efficacy and safety of tamoxifen for mastoplasia. Methods： Searches were applied to following electronic databases： MEDLINE, EMBASE, BIOSIS and Cochrane Library. Chinese conference proceedings were handsearched. Those control trials, in which patients were treated with tamoxifen and traditional chinese medicine, were selected. The dosage, using method and course of treatment of tamoxifen were not restricted. Results： 5 trials, including 3 089 patients, met the inclusion critoria, and 3 of them mentioned random grouping. The combined results showed that it had a certain positive effect to treat mastoplasia with tamoxifen. （ the relative risk of no avail was 1.88, 95% confidence interval was 0. 22 - 15.72）. Side-effects were reported in these trials, but it graduated away after stopping the treatment. Conclusions： According to the systematic review, treatment with tamoxifen for mastoplasia has a certain positive effect, but may produce reversible side-effect. However, the evidence is not enough due to the general low methodological quality. Trails with large samples are needed.
出处
《四川肿瘤防治》
2006年第1期17-20,共4页
Sichuan Journal of Cancer Control
